GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

iTeos Therapeutics, Inc. has announced a definitive merger agreement with Concentra Biosciences, LLC, under which Concentra will acquire iTeos for $10.047 in cash per share, along with a non ...

Immuno-oncology drug developer iTeos Therapeutics (NASDAQ:ITOS) on Monday said it has entered into an agreement to be acquired by Concentra Biosciences for $10.047 in cash per share plus a ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra ...

Belgium-based iTeos decided in May that with its TIGIT dreams in ruins, its best bet was to wind down operations, sell its assets and return as much of its $600 million-plus cash pile to investors ...

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company’s lead ...

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates iTeos Therapeutics Inc. - GlobeNewswire - Wed Mar 5, 6:00AM CST ...

Investors in iTeos Therapeutics, Inc. (NASDAQ:ITOS) have tasted that bitter downside in the last year, as the share price dropped 46%. That's disappointing when you consider the market declined 2.5%.

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...

--iTeos Therapeutics, Inc. today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC will acquire iTeos for $10.047 in cash per share of iTeos ...

iTeos on Monday said Concentra will pay nearly $10.05 a share in cash for the Watertown, Mass., clinical-stage biopharmaceutical company, about 2% below Friday's closing price of $10.26.